-
Mashup Score: 0
The use of race in medicine has recently come to a reckoning,1,2 and the field of cancer genomics is not exempt from this critical introspection. Race must be understood as a social construct in scientific pursuits, yet equitable genomics research requires adequate racial representation and diversity.3 To overcome this challenge, large registries of real-world genetic data have been assembled to…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer - 1 year(s) ago
PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET,…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer https://t.co/64Pkdzfh2m @JCOPO_ASCO @DanaFarber_Hale #OpenAccess https://t.co/76k1DPzk29
-
-
Mashup Score: 1
PURPOSE Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United States compared with single-gene testing (SGT) in patients with metastatic nonsquamous…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
For nonsquamous NSCLC, biomarker testing with NGS is costly - but could it lead to cost savings overall? This work @JCOPO_ASCO by Dr. @n8pennell and team show that every 10% increase in NGS use produces 2627 life years gained and SAVES $75 per LYG! https://t.co/sR9wKqA0yK
-
-
Mashup Score: 2
PURPOSE Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United States compared with single-gene testing (SGT) in patients with metastatic nonsquamous…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
For nonsquamous NSCLC, biomarker testing with NGS is costly - but could it lead to cost savings overall? This work @JCO_ASCO by Dr. @n8pennell and team show that every 10% increase in NGS use produces 2627 life years gained and SAVES $75 per LYG! https://t.co/sR9wKqA0yK
-
-
Mashup Score: 0STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer - 1 year(s) ago
PURPOSE Molecular factors predicting relapse in early-stage non–small-cell lung cancer (ES-NSCLC) are poorly understood, especially in inoperable patients receiving radiotherapy (RT). In this study, we compared the genomic profiles of inoperable and operable ES-NSCLC. MATERIALS AND METHODS This retrospective study included 53 patients with nonsquamous ES-NSCLC (stage I-II) treated at a single…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non–Small-Cell Lung Cancer [ Jan 5, 2023] @RohanKatipally et al. @JCOPO_ASCO https://t.co/ggsHZosKUC #lcsm #PrecisionMedicine https://t.co/PPcHoV6Rnh
-
-
Mashup Score: 1Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board - 1 year(s) ago
Purpose Precision oncology develops and implements evidence-based personalized therapies that are based on specific genetic targets within each tumor. However, a major challenge that remains is the provision of a standardized, up-to-date, and evidenced-based precision medicine initiative across a geographic region. Materials and Methods We developed a statewide molecular tumor board that…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine MTB [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO https://t.co/HOWIx826Lm
-
-
Mashup Score: 1Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance - 1 year(s) ago
PURPOSE Molecular tumor boards (MTBs) provide interventions that assist the patient’s primary oncologist’s interpretation and application of precision oncology and avoid clinical and financial toxicities of prescribing inappropriate targeted therapy. In this article, we describe a novel method for illustrating MTBs value and recommendation discordance rate and report associated drug cost…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO https://t.co/OORXChCe95 #PrecisionMedicine #hpeonc https://t.co/w7MzX1pbQh
-
-
Mashup Score: 0Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance - 1 year(s) ago
PURPOSE Molecular tumor boards (MTBs) provide interventions that assist the patient’s primary oncologist’s interpretation and application of precision oncology and avoid clinical and financial toxicities of prescribing inappropriate targeted therapy. In this article, we describe a novel method for illustrating MTBs value and recommendation discordance rate and report associated drug cost…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO https://t.co/OORXChBGjx #PrecisionMedicine #hpeonc https://t.co/0lFBVExPWO
-
-
Mashup Score: 1
PURPOSE In head and neck squamous cell carcinoma (HNSCC), HRAS mutation is a new actionable oncogene driver. We aimed to evaluate HRAS mutational variants, comutation profile, and survival outcomes of this molecularly defined population. METHODS We leveraged four deidentified patient data sets with HRAS-mutant HNSCC, MD Anderson Cancer Center, Kura Oncology, Inc trial, Foundation Medicine, and…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma | JCO Precision Oncology https://t.co/d38w7ZRndz
-
-
Mashup Score: 1Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib - 1 year(s) ago
We report small cell transformation in a patient with a RET fusion lung cancer treated with targeted therapy.
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib https://t.co/J2GFUqdviJ
-
As well as our work in @JCOPO_ASCO https://t.co/cxrQwSjSIT This evaluated whether data within #ProjectGenie was sufficient to detect differences in mutational frequencies or distributions between racial groups. We found that, at time of analysis, 3/n